Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 188 | 2024 | 21012 | 11.570 |
Why?
|
Receptor, erbB-2 | 102 | 2024 | 2557 | 10.650 |
Why?
|
Immunoconjugates | 35 | 2024 | 954 | 7.080 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 103 | 2024 | 11742 | 5.800 |
Why?
|
Paclitaxel | 28 | 2024 | 1732 | 3.760 |
Why?
|
Camptothecin | 26 | 2024 | 591 | 3.480 |
Why?
|
Aminopyridines | 21 | 2024 | 573 | 3.070 |
Why?
|
Receptors, Progesterone | 21 | 2024 | 1129 | 3.020 |
Why?
|
Receptors, Estrogen | 32 | 2024 | 2208 | 3.010 |
Why?
|
Cyclin-Dependent Kinase 4 | 15 | 2024 | 561 | 3.010 |
Why?
|
Benzimidazoles | 17 | 2024 | 858 | 2.890 |
Why?
|
Neoadjuvant Therapy | 34 | 2024 | 2827 | 2.540 |
Why?
|
Ketones | 5 | 2024 | 184 | 2.450 |
Why?
|
Furans | 5 | 2024 | 202 | 2.430 |
Why?
|
Cyclin-Dependent Kinase 6 | 8 | 2024 | 350 | 2.290 |
Why?
|
Antineoplastic Agents | 31 | 2024 | 13639 | 1.990 |
Why?
|
Maytansine | 4 | 2022 | 86 | 1.830 |
Why?
|
Chemotherapy, Adjuvant | 27 | 2024 | 3514 | 1.730 |
Why?
|
Protein Kinase Inhibitors | 23 | 2024 | 5671 | 1.700 |
Why?
|
Pyridines | 14 | 2024 | 2875 | 1.670 |
Why?
|
Anilides | 6 | 2020 | 411 | 1.660 |
Why?
|
Molecular Targeted Therapy | 11 | 2024 | 2811 | 1.600 |
Why?
|
Female | 228 | 2024 | 392644 | 1.510 |
Why?
|
Neoplasm Metastasis | 29 | 2024 | 4915 | 1.240 |
Why?
|
Humans | 271 | 2024 | 761504 | 1.200 |
Why?
|
Immunotherapy | 18 | 2024 | 4652 | 1.190 |
Why?
|
Lung Diseases, Interstitial | 4 | 2024 | 918 | 1.180 |
Why?
|
Endocrine System Diseases | 3 | 2018 | 249 | 1.160 |
Why?
|
Neoplasm Staging | 31 | 2024 | 11121 | 1.100 |
Why?
|
Neoplasm Recurrence, Local | 26 | 2024 | 9280 | 1.070 |
Why?
|
Breast Neoplasms, Male | 7 | 2024 | 219 | 1.030 |
Why?
|
Brain Neoplasms | 12 | 2024 | 9031 | 0.990 |
Why?
|
Disease-Free Survival | 20 | 2024 | 6814 | 0.970 |
Why?
|
Aromatase Inhibitors | 3 | 2024 | 513 | 0.960 |
Why?
|
Inflammatory Breast Neoplasms | 5 | 2024 | 147 | 0.960 |
Why?
|
Cisplatin | 2 | 2021 | 1651 | 0.950 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 7 | 2024 | 1092 | 0.910 |
Why?
|
Tumor Microenvironment | 11 | 2024 | 3877 | 0.910 |
Why?
|
Middle Aged | 109 | 2024 | 220895 | 0.850 |
Why?
|
Tetrahydronaphthalenes | 1 | 2023 | 86 | 0.830 |
Why?
|
Clinical Trials as Topic | 8 | 2024 | 8002 | 0.760 |
Why?
|
Neoplasms | 23 | 2024 | 22170 | 0.760 |
Why?
|
Piperazines | 7 | 2024 | 2523 | 0.740 |
Why?
|
Neutropenia | 5 | 2023 | 885 | 0.730 |
Why?
|
Aged | 84 | 2024 | 169289 | 0.730 |
Why?
|
Research Subjects | 1 | 2021 | 249 | 0.670 |
Why?
|
Adult | 86 | 2024 | 221177 | 0.650 |
Why?
|
Quinoxalines | 3 | 2016 | 296 | 0.650 |
Why?
|
Maximum Tolerated Dose | 7 | 2024 | 883 | 0.640 |
Why?
|
Estrogen Receptor alpha | 2 | 2023 | 582 | 0.640 |
Why?
|
Neoplasms, Second Primary | 2 | 2022 | 1052 | 0.640 |
Why?
|
Genes, erbB-2 | 1 | 2019 | 162 | 0.630 |
Why?
|
Endpoint Determination | 1 | 2021 | 590 | 0.610 |
Why?
|
Prognosis | 29 | 2024 | 29625 | 0.610 |
Why?
|
Pyrimidinones | 1 | 2020 | 385 | 0.600 |
Why?
|
Taxoids | 4 | 2023 | 668 | 0.600 |
Why?
|
Treatment Outcome | 44 | 2024 | 64680 | 0.580 |
Why?
|
Quinolines | 4 | 2019 | 764 | 0.570 |
Why?
|
Carcinoma, Ductal, Breast | 2 | 2020 | 1085 | 0.570 |
Why?
|
Antigens, Neoplasm | 10 | 2024 | 1993 | 0.570 |
Why?
|
Quality of Life | 15 | 2024 | 13367 | 0.560 |
Why?
|
Drug Resistance, Neoplasm | 12 | 2024 | 5305 | 0.560 |
Why?
|
Pyrazoles | 3 | 2024 | 2009 | 0.540 |
Why?
|
Antineoplastic Agents, Hormonal | 7 | 2024 | 1520 | 0.540 |
Why?
|
Amenorrhea | 2 | 2021 | 483 | 0.530 |
Why?
|
Antigens, Surface | 1 | 2020 | 1606 | 0.520 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2016 | 571 | 0.500 |
Why?
|
Pyrrolidinones | 1 | 2015 | 116 | 0.480 |
Why?
|
Fluorouracil | 2 | 2022 | 1641 | 0.460 |
Why?
|
PTEN Phosphohydrolase | 1 | 2020 | 1115 | 0.450 |
Why?
|
Nitriles | 5 | 2024 | 971 | 0.450 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 546 | 0.450 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2020 | 2865 | 0.450 |
Why?
|
Deoxycytidine | 2 | 2018 | 877 | 0.440 |
Why?
|
Antibodies, Monoclonal | 6 | 2021 | 9177 | 0.440 |
Why?
|
Randomized Controlled Trials as Topic | 9 | 2024 | 10209 | 0.430 |
Why?
|
Biological Products | 1 | 2022 | 914 | 0.430 |
Why?
|
Thyroid Diseases | 4 | 2024 | 386 | 0.420 |
Why?
|
Mastectomy | 5 | 2022 | 1822 | 0.410 |
Why?
|
Diarrhea | 7 | 2024 | 1318 | 0.400 |
Why?
|
Neoplasm, Residual | 4 | 2024 | 1008 | 0.400 |
Why?
|
Mutation | 19 | 2024 | 30052 | 0.390 |
Why?
|
Cell Adhesion Molecules | 6 | 2024 | 1600 | 0.380 |
Why?
|
Cyclophosphamide | 6 | 2022 | 2218 | 0.380 |
Why?
|
Genomics | 8 | 2024 | 5821 | 0.370 |
Why?
|
Sulfonamides | 3 | 2016 | 1978 | 0.370 |
Why?
|
Breast | 6 | 2023 | 1967 | 0.370 |
Why?
|
Infusions, Intravenous | 4 | 2021 | 2219 | 0.370 |
Why?
|
Aged, 80 and over | 25 | 2024 | 58976 | 0.360 |
Why?
|
Pneumonia, Pneumocystis | 2 | 2015 | 242 | 0.360 |
Why?
|
Mastectomy, Segmental | 4 | 2021 | 955 | 0.340 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 646 | 0.340 |
Why?
|
Quinazolines | 6 | 2024 | 1371 | 0.340 |
Why?
|
Purines | 4 | 2023 | 607 | 0.340 |
Why?
|
Polyethylene Glycols | 5 | 2022 | 1189 | 0.340 |
Why?
|
Clinical Trials, Phase II as Topic | 4 | 2021 | 629 | 0.330 |
Why?
|
Tumor Burden | 5 | 2021 | 1893 | 0.310 |
Why?
|
Hormones | 6 | 2023 | 869 | 0.310 |
Why?
|
Survival Rate | 8 | 2021 | 12725 | 0.300 |
Why?
|
Follow-Up Studies | 13 | 2024 | 39106 | 0.300 |
Why?
|
Drug Administration Schedule | 5 | 2020 | 4853 | 0.300 |
Why?
|
Carcinoma | 1 | 2019 | 2330 | 0.290 |
Why?
|
Disease Management | 4 | 2020 | 2508 | 0.290 |
Why?
|
Referral and Consultation | 1 | 2020 | 3600 | 0.280 |
Why?
|
Albumins | 2 | 2020 | 575 | 0.280 |
Why?
|
Neovascularization, Pathologic | 2 | 2024 | 2645 | 0.270 |
Why?
|
Retinoblastoma Binding Proteins | 2 | 2024 | 101 | 0.270 |
Why?
|
Topoisomerase I Inhibitors | 2 | 2024 | 70 | 0.270 |
Why?
|
Immunologic Factors | 4 | 2023 | 1589 | 0.260 |
Why?
|
Lymphopenia | 1 | 2008 | 281 | 0.260 |
Why?
|
Kaplan-Meier Estimate | 6 | 2024 | 6484 | 0.260 |
Why?
|
Research Design | 2 | 2023 | 6180 | 0.260 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2024 | 8547 | 0.260 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 5315 | 0.260 |
Why?
|
Attitude of Health Personnel | 1 | 2020 | 3889 | 0.260 |
Why?
|
Triazoles | 3 | 2017 | 903 | 0.260 |
Why?
|
Medical Oncology | 6 | 2024 | 2321 | 0.260 |
Why?
|
Survival Analysis | 7 | 2021 | 10090 | 0.260 |
Why?
|
Filgrastim | 3 | 2020 | 132 | 0.260 |
Why?
|
Combined Modality Therapy | 5 | 2021 | 8529 | 0.260 |
Why?
|
Oxazoles | 3 | 2024 | 199 | 0.260 |
Why?
|
Receptor, erbB-3 | 2 | 2016 | 143 | 0.260 |
Why?
|
Ki-67 Antigen | 3 | 2023 | 629 | 0.260 |
Why?
|
DNA Copy Number Variations | 4 | 2024 | 2020 | 0.250 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2020 | 4016 | 0.250 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2022 | 899 | 0.250 |
Why?
|
Young Adult | 15 | 2024 | 59243 | 0.250 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2016 | 2118 | 0.240 |
Why?
|
Palliative Care | 1 | 2020 | 3598 | 0.240 |
Why?
|
Breast Diseases | 1 | 2007 | 442 | 0.230 |
Why?
|
BRCA2 Protein | 3 | 2023 | 805 | 0.220 |
Why?
|
Receptors, Androgen | 2 | 2024 | 1079 | 0.220 |
Why?
|
Physical Fitness | 3 | 2017 | 743 | 0.220 |
Why?
|
Doxorubicin | 4 | 2020 | 2224 | 0.220 |
Why?
|
Anthracyclines | 3 | 2021 | 284 | 0.220 |
Why?
|
Exercise Therapy | 3 | 2020 | 929 | 0.210 |
Why?
|
Epirubicin | 1 | 2022 | 81 | 0.210 |
Why?
|
Axilla | 2 | 2023 | 624 | 0.210 |
Why?
|
Ventricular Function, Left | 1 | 2016 | 3879 | 0.210 |
Why?
|
Dose-Response Relationship, Drug | 9 | 2020 | 10766 | 0.210 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2021 | 857 | 0.200 |
Why?
|
Biopsy | 4 | 2024 | 6766 | 0.200 |
Why?
|
Acupuncture, Ear | 1 | 2022 | 13 | 0.200 |
Why?
|
Androstadienes | 1 | 2024 | 348 | 0.200 |
Why?
|
High-Throughput Nucleotide Sequencing | 3 | 2024 | 3639 | 0.200 |
Why?
|
BRCA1 Protein | 3 | 2023 | 1155 | 0.200 |
Why?
|
Sarcoidosis | 1 | 2007 | 521 | 0.200 |
Why?
|
Stroke Volume | 1 | 2016 | 5496 | 0.200 |
Why?
|
Sulfides | 1 | 2022 | 169 | 0.190 |
Why?
|
Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2021 | 53 | 0.190 |
Why?
|
Thyrotoxicosis | 2 | 2019 | 85 | 0.190 |
Why?
|
Purinergic P1 Receptor Antagonists | 1 | 2021 | 45 | 0.190 |
Why?
|
Cohort Studies | 8 | 2024 | 41487 | 0.190 |
Why?
|
Drug Interactions | 2 | 2023 | 1416 | 0.190 |
Why?
|
Lymph Nodes | 3 | 2023 | 3466 | 0.190 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2023 | 732 | 0.190 |
Why?
|
Endocrine Glands | 2 | 2018 | 102 | 0.180 |
Why?
|
High-Intensity Focused Ultrasound Ablation | 1 | 2021 | 40 | 0.180 |
Why?
|
Sweden | 1 | 2024 | 1379 | 0.180 |
Why?
|
SEER Program | 5 | 2024 | 1450 | 0.180 |
Why?
|
Cell Cycle Proteins | 3 | 2020 | 3448 | 0.170 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 926 | 0.170 |
Why?
|
Gene Expression Profiling | 4 | 2024 | 9420 | 0.170 |
Why?
|
Fatigue | 5 | 2022 | 1552 | 0.170 |
Why?
|
Meningeal Carcinomatosis | 1 | 2020 | 63 | 0.170 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2024 | 736 | 0.170 |
Why?
|
Antigen Presentation | 2 | 2023 | 1251 | 0.170 |
Why?
|
Argentina | 1 | 2020 | 246 | 0.170 |
Why?
|
Prednisone | 2 | 2019 | 1563 | 0.170 |
Why?
|
Opportunistic Infections | 2 | 2015 | 376 | 0.170 |
Why?
|
Lymph Node Excision | 2 | 2023 | 1271 | 0.160 |
Why?
|
Immunohistochemistry | 4 | 2024 | 11076 | 0.160 |
Why?
|
Disease Progression | 6 | 2024 | 13506 | 0.160 |
Why?
|
Estradiol | 2 | 2017 | 1937 | 0.160 |
Why?
|
Drugs, Investigational | 1 | 2021 | 212 | 0.160 |
Why?
|
Ligands | 2 | 2023 | 3272 | 0.160 |
Why?
|
Internationality | 1 | 2024 | 1001 | 0.160 |
Why?
|
GPI-Linked Proteins | 1 | 2020 | 469 | 0.160 |
Why?
|
Addison Disease | 1 | 2019 | 48 | 0.160 |
Why?
|
Artificial Intelligence | 2 | 2023 | 2578 | 0.160 |
Why?
|
Cancer Vaccines | 2 | 2023 | 1051 | 0.160 |
Why?
|
Perforin | 1 | 2018 | 167 | 0.150 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2024 | 2455 | 0.150 |
Why?
|
Retreatment | 2 | 2020 | 598 | 0.150 |
Why?
|
Community-Based Participatory Research | 1 | 2020 | 221 | 0.150 |
Why?
|
Nausea | 5 | 2022 | 679 | 0.150 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2024 | 2510 | 0.150 |
Why?
|
Republic of Korea | 1 | 2020 | 590 | 0.150 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 732 | 0.150 |
Why?
|
Poisson Distribution | 1 | 2019 | 504 | 0.150 |
Why?
|
DNA, Neoplasm | 2 | 2017 | 1745 | 0.150 |
Why?
|
Central Nervous System Neoplasms | 2 | 2024 | 916 | 0.150 |
Why?
|
Lymphatic Metastasis | 3 | 2021 | 2915 | 0.150 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2021 | 678 | 0.140 |
Why?
|
Tamoxifen | 2 | 2013 | 965 | 0.140 |
Why?
|
Morpholines | 1 | 2020 | 581 | 0.140 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6346 | 0.140 |
Why?
|
Incidence | 6 | 2022 | 21353 | 0.140 |
Why?
|
Hypothyroidism | 2 | 2019 | 668 | 0.140 |
Why?
|
Patient Selection | 4 | 2024 | 4244 | 0.140 |
Why?
|
Ovarian Neoplasms | 3 | 2020 | 4876 | 0.140 |
Why?
|
Retrospective Studies | 14 | 2024 | 80636 | 0.140 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2024 | 3415 | 0.140 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2016 | 64 | 0.140 |
Why?
|
Hyperglycemia | 2 | 2022 | 1376 | 0.140 |
Why?
|
Thiazoles | 2 | 2022 | 1517 | 0.130 |
Why?
|
North America | 1 | 2020 | 1276 | 0.130 |
Why?
|
Australia | 1 | 2020 | 1250 | 0.130 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2019 | 1784 | 0.130 |
Why?
|
Prospective Studies | 10 | 2024 | 54425 | 0.130 |
Why?
|
Safety | 1 | 2021 | 1150 | 0.130 |
Why?
|
Disease Susceptibility | 2 | 2020 | 1787 | 0.130 |
Why?
|
Europe | 2 | 2020 | 3422 | 0.130 |
Why?
|
Brazil | 1 | 2020 | 1230 | 0.130 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2018 | 592 | 0.130 |
Why?
|
United States | 11 | 2024 | 72334 | 0.130 |
Why?
|
Guidelines as Topic | 2 | 2021 | 1386 | 0.130 |
Why?
|
Metformin | 2 | 2020 | 906 | 0.120 |
Why?
|
Lung Neoplasms | 6 | 2023 | 13380 | 0.120 |
Why?
|
Pneumocystis carinii | 1 | 2015 | 72 | 0.120 |
Why?
|
Drug Therapy, Combination | 2 | 2024 | 6310 | 0.120 |
Why?
|
NF-kappa B | 1 | 2023 | 2490 | 0.120 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 1 | 2018 | 269 | 0.120 |
Why?
|
Estrogens | 1 | 2021 | 1522 | 0.120 |
Why?
|
Diabetes Mellitus | 2 | 2024 | 5840 | 0.120 |
Why?
|
Cell Line, Tumor | 9 | 2024 | 16981 | 0.120 |
Why?
|
Cross-Over Studies | 1 | 2020 | 2078 | 0.120 |
Why?
|
Melanoma | 2 | 2023 | 5709 | 0.120 |
Why?
|
Phthalazines | 3 | 2024 | 383 | 0.120 |
Why?
|
Pyrimidines | 2 | 2024 | 3028 | 0.120 |
Why?
|
Male | 26 | 2024 | 360804 | 0.110 |
Why?
|
Endometrial Neoplasms | 1 | 2023 | 1366 | 0.110 |
Why?
|
Immunomodulation | 1 | 2017 | 549 | 0.110 |
Why?
|
Drug Synergism | 3 | 2024 | 1755 | 0.110 |
Why?
|
Tosyl Compounds | 1 | 2013 | 115 | 0.110 |
Why?
|
Epothilones | 1 | 2013 | 42 | 0.110 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2449 | 0.110 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2013 | 107 | 0.110 |
Why?
|
Time Factors | 6 | 2024 | 39967 | 0.110 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2019 | 710 | 0.110 |
Why?
|
Hepatitis C | 1 | 2023 | 1584 | 0.100 |
Why?
|
Interleukin-6 | 2 | 2024 | 3208 | 0.100 |
Why?
|
RNA | 1 | 2022 | 2726 | 0.100 |
Why?
|
Information Dissemination | 1 | 2021 | 1126 | 0.100 |
Why?
|
Health Care Surveys | 1 | 2019 | 2426 | 0.100 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2021 | 4580 | 0.100 |
Why?
|
Pyrroles | 1 | 2018 | 1125 | 0.100 |
Why?
|
Pneumonia | 1 | 2023 | 2143 | 0.100 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2023 | 15936 | 0.090 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2425 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2024 | 2057 | 0.090 |
Why?
|
Proportional Hazards Models | 3 | 2023 | 12463 | 0.090 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 410 | 0.090 |
Why?
|
Drug Therapy | 1 | 2014 | 503 | 0.090 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2013 | 424 | 0.090 |
Why?
|
Carcinoma, Papillary | 2 | 2006 | 785 | 0.090 |
Why?
|
Societies, Medical | 2 | 2021 | 3905 | 0.090 |
Why?
|
Estrogen Receptor Modulators | 1 | 2010 | 58 | 0.090 |
Why?
|
Decision Making | 2 | 2021 | 3929 | 0.090 |
Why?
|
Genotype | 3 | 2023 | 12990 | 0.090 |
Why?
|
Factor V | 1 | 2010 | 167 | 0.080 |
Why?
|
Piperidines | 1 | 2018 | 1656 | 0.080 |
Why?
|
Platinum | 2 | 2021 | 220 | 0.080 |
Why?
|
Exercise | 4 | 2021 | 5890 | 0.080 |
Why?
|
Preoperative Care | 2 | 2019 | 2242 | 0.080 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2021 | 2223 | 0.080 |
Why?
|
Neoplasms, Glandular and Epithelial | 1 | 2013 | 487 | 0.080 |
Why?
|
Administration, Oral | 2 | 2014 | 4021 | 0.080 |
Why?
|
Odds Ratio | 2 | 2019 | 9646 | 0.080 |
Why?
|
Biomedical Research | 1 | 2024 | 3429 | 0.080 |
Why?
|
Mice | 9 | 2024 | 81525 | 0.080 |
Why?
|
Signal Transduction | 3 | 2021 | 23445 | 0.080 |
Why?
|
Genome, Human | 1 | 2021 | 4425 | 0.080 |
Why?
|
Gene Expression | 1 | 2021 | 7581 | 0.080 |
Why?
|
Radiotherapy | 1 | 2015 | 1499 | 0.070 |
Why?
|
Vomiting | 2 | 2022 | 651 | 0.070 |
Why?
|
Granulocyte Colony-Stimulating Factor | 2 | 2006 | 629 | 0.070 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2018 | 3492 | 0.070 |
Why?
|
Risk | 1 | 2019 | 9610 | 0.070 |
Why?
|
Gene Dosage | 2 | 2024 | 1217 | 0.070 |
Why?
|
Recurrence | 1 | 2019 | 8465 | 0.070 |
Why?
|
Cytokines | 1 | 2021 | 7396 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2024 | 3602 | 0.070 |
Why?
|
Genetic Testing | 1 | 2019 | 3537 | 0.070 |
Why?
|
Survivors | 1 | 2016 | 2371 | 0.070 |
Why?
|
Glioblastoma | 1 | 2021 | 3482 | 0.060 |
Why?
|
Carboplatin | 2 | 2022 | 794 | 0.060 |
Why?
|
Obesity | 2 | 2018 | 12947 | 0.060 |
Why?
|
Antiemetics | 1 | 2006 | 186 | 0.060 |
Why?
|
Hematopoietic Stem Cell Mobilization | 1 | 2006 | 225 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 5 | 2017 | 20570 | 0.060 |
Why?
|
Risk Factors | 8 | 2023 | 74206 | 0.060 |
Why?
|
Androgen Antagonists | 1 | 2013 | 1410 | 0.060 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 263 | 0.060 |
Why?
|
Oxazepines | 1 | 2024 | 22 | 0.060 |
Why?
|
Cost-Benefit Analysis | 1 | 2017 | 5492 | 0.060 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2024 | 106 | 0.060 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2021 | 9000 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 2 | 2019 | 1809 | 0.060 |
Why?
|
Thromboembolism | 1 | 2010 | 995 | 0.060 |
Why?
|
Animals | 9 | 2024 | 168459 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 1 | 2013 | 2047 | 0.050 |
Why?
|
Ubiquitin-Protein Ligases | 2 | 2024 | 1897 | 0.050 |
Why?
|
Uracil | 1 | 2024 | 207 | 0.050 |
Why?
|
Receptors, KIR | 1 | 2023 | 110 | 0.050 |
Why?
|
Risk Assessment | 3 | 2024 | 23995 | 0.050 |
Why?
|
Thyroid Neoplasms | 2 | 2006 | 2332 | 0.050 |
Why?
|
United States Food and Drug Administration | 2 | 2021 | 1664 | 0.050 |
Why?
|
CD4 Lymphocyte Count | 1 | 2008 | 2571 | 0.050 |
Why?
|
Genes, Tumor Suppressor | 1 | 2006 | 1062 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 2 | 2023 | 1135 | 0.050 |
Why?
|
Biology | 1 | 2024 | 290 | 0.050 |
Why?
|
Double-Blind Method | 3 | 2024 | 12341 | 0.050 |
Why?
|
Registries | 3 | 2023 | 8224 | 0.050 |
Why?
|
Heart Diseases | 1 | 2014 | 2781 | 0.050 |
Why?
|
Retinoblastoma Protein | 1 | 2024 | 672 | 0.050 |
Why?
|
Premedication | 1 | 2021 | 246 | 0.050 |
Why?
|
Inflammation | 1 | 2020 | 10773 | 0.040 |
Why?
|
Colorectal Neoplasms | 1 | 2020 | 6935 | 0.040 |
Why?
|
Blood Glucose Self-Monitoring | 1 | 2024 | 467 | 0.040 |
Why?
|
Gene Silencing | 1 | 2006 | 1509 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2006 | 6534 | 0.040 |
Why?
|
Immunotoxins | 1 | 2020 | 175 | 0.040 |
Why?
|
Organ Specificity | 1 | 2024 | 1967 | 0.040 |
Why?
|
Receptors, IgG | 1 | 2023 | 559 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 326 | 0.040 |
Why?
|
Receptors, Steroid | 1 | 2020 | 156 | 0.040 |
Why?
|
Hypoglycemic Agents | 2 | 2024 | 3085 | 0.040 |
Why?
|
Germ Cells | 1 | 2023 | 634 | 0.040 |
Why?
|
Personal Satisfaction | 1 | 2024 | 644 | 0.040 |
Why?
|
Anti-Infective Agents | 1 | 2006 | 983 | 0.040 |
Why?
|
Alleles | 2 | 2022 | 6863 | 0.040 |
Why?
|
Dexamethasone | 1 | 2006 | 1948 | 0.040 |
Why?
|
Cell Death | 1 | 2024 | 1678 | 0.040 |
Why?
|
Transplantation Conditioning | 1 | 2006 | 1590 | 0.040 |
Why?
|
Fever | 1 | 2006 | 1618 | 0.040 |
Why?
|
Workflow | 1 | 2023 | 851 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 17904 | 0.040 |
Why?
|
Thrombocytopenia | 2 | 2018 | 1181 | 0.040 |
Why?
|
Mind-Body Therapies | 1 | 2021 | 279 | 0.040 |
Why?
|
Observer Variation | 1 | 2024 | 2606 | 0.040 |
Why?
|
Weight Loss | 2 | 2021 | 2684 | 0.040 |
Why?
|
Imidazoles | 1 | 2024 | 1180 | 0.040 |
Why?
|
Patient Care | 1 | 2023 | 622 | 0.040 |
Why?
|
Epigenomics | 1 | 2023 | 943 | 0.040 |
Why?
|
Body Composition | 2 | 2017 | 2426 | 0.040 |
Why?
|
Prevalence | 3 | 2024 | 15732 | 0.040 |
Why?
|
Computational Biology | 2 | 2021 | 3518 | 0.040 |
Why?
|
Mitochondrial Proteins | 1 | 2023 | 976 | 0.040 |
Why?
|
Immunosuppressive Agents | 2 | 2022 | 4174 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2018 | 247 | 0.040 |
Why?
|
Premenopause | 1 | 2021 | 1039 | 0.040 |
Why?
|
Half-Life | 1 | 2018 | 651 | 0.040 |
Why?
|
Anemia | 2 | 2019 | 1509 | 0.030 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2018 | 350 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2024 | 2020 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 2024 | 10194 | 0.030 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2016 | 2057 | 0.030 |
Why?
|
Positron-Emission Tomography | 2 | 2013 | 6485 | 0.030 |
Why?
|
Central Nervous System | 1 | 2022 | 1336 | 0.030 |
Why?
|
Germ-Line Mutation | 1 | 2023 | 1858 | 0.030 |
Why?
|
Recombinant Fusion Proteins | 1 | 2023 | 3734 | 0.030 |
Why?
|
Patient Preference | 1 | 2022 | 924 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2024 | 36426 | 0.030 |
Why?
|
Hematologic Neoplasms | 1 | 2006 | 1896 | 0.030 |
Why?
|
Amino Acid Substitution | 1 | 2018 | 1738 | 0.030 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2016 | 426 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2022 | 3778 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3123 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 2872 | 0.030 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2547 | 0.030 |
Why?
|
Tablets | 1 | 2013 | 148 | 0.030 |
Why?
|
Capsules | 1 | 2013 | 191 | 0.030 |
Why?
|
DNA Methylation | 1 | 2006 | 4398 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1745 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 12974 | 0.020 |
Why?
|
Peptides | 1 | 2024 | 4358 | 0.020 |
Why?
|
Developing Countries | 1 | 2024 | 2885 | 0.020 |
Why?
|
Disease Models, Animal | 3 | 2016 | 18252 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1768 | 0.020 |
Why?
|
Stomatitis | 1 | 2013 | 271 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2022 | 8181 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2022 | 5247 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2022 | 4740 | 0.020 |
Why?
|
Algorithms | 2 | 2022 | 14031 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 3810 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 1722 | 0.020 |
Why?
|
Drug Monitoring | 1 | 2016 | 962 | 0.020 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 664 | 0.020 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2010 | 132 | 0.020 |
Why?
|
Autoimmunity | 1 | 2018 | 1356 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3416 | 0.020 |
Why?
|
Macrophages | 1 | 2024 | 5769 | 0.020 |
Why?
|
Multiprotein Complexes | 1 | 2016 | 1118 | 0.020 |
Why?
|
Area Under Curve | 1 | 2013 | 1638 | 0.020 |
Why?
|
Mice, Nude | 1 | 2016 | 3615 | 0.020 |
Why?
|
Blood Glucose | 1 | 2024 | 6391 | 0.020 |
Why?
|
Gene Amplification | 1 | 2013 | 1089 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4111 | 0.020 |
Why?
|
Reference Values | 1 | 2016 | 4920 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3826 | 0.020 |
Why?
|
Remission Induction | 1 | 2014 | 2396 | 0.020 |
Why?
|
Mitosis | 1 | 2013 | 1187 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2013 | 1334 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 3617 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3595 | 0.020 |
Why?
|
Apoptosis | 1 | 2023 | 9486 | 0.020 |
Why?
|
Pain | 1 | 2022 | 5073 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2023 | 14605 | 0.020 |
Why?
|
Tissue Inhibitor of Metalloproteinase-3 | 1 | 2006 | 34 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2024 | 11528 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2016 | 1943 | 0.020 |
Why?
|
Monocarboxylic Acid Transporters | 1 | 2006 | 80 | 0.020 |
Why?
|
Sirolimus | 1 | 2013 | 1533 | 0.020 |
Why?
|
DNA Repair | 1 | 2016 | 2045 | 0.020 |
Why?
|
Ambulatory Care | 1 | 2017 | 2775 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2015 | 1880 | 0.020 |
Why?
|
Population Surveillance | 1 | 2016 | 2598 | 0.020 |
Why?
|
Receptors, Retinoic Acid | 1 | 2006 | 224 | 0.020 |
Why?
|
Rats | 1 | 2022 | 23742 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2016 | 22176 | 0.020 |
Why?
|
Life Style | 1 | 2017 | 3917 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2016 | 2803 | 0.020 |
Why?
|
Postmenopause | 1 | 2014 | 2513 | 0.020 |
Why?
|
Histones | 1 | 2016 | 2580 | 0.020 |
Why?
|
Myeloablative Agonists | 1 | 2006 | 209 | 0.020 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 489 | 0.020 |
Why?
|
Self Report | 1 | 2016 | 3724 | 0.020 |
Why?
|
Mucositis | 1 | 2006 | 108 | 0.020 |
Why?
|
Phosphorylation | 1 | 2016 | 8320 | 0.010 |
Why?
|
Etoposide | 1 | 2006 | 634 | 0.010 |
Why?
|
Cation Transport Proteins | 1 | 2006 | 327 | 0.010 |
Why?
|
DNA Damage | 1 | 2013 | 2446 | 0.010 |
Why?
|
Software | 1 | 2017 | 4434 | 0.010 |
Why?
|
Mammaplasty | 1 | 2013 | 1239 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2016 | 9539 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10445 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2021 | 22169 | 0.010 |
Why?
|
Cardiomyopathies | 1 | 2014 | 1964 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8654 | 0.010 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2006 | 621 | 0.010 |
Why?
|
Cell Movement | 1 | 2013 | 5203 | 0.010 |
Why?
|
Nuclear Proteins | 1 | 2016 | 5796 | 0.010 |
Why?
|
Transplantation, Autologous | 1 | 2006 | 2115 | 0.010 |
Why?
|
Comorbidity | 1 | 2015 | 10508 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 7390 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4575 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2010 | 12059 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13255 | 0.010 |
Why?
|
Graft Survival | 1 | 2006 | 3819 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 11118 | 0.010 |
Why?
|
Adolescent | 1 | 2022 | 88319 | 0.010 |
Why?
|
Hypertension | 1 | 2014 | 8540 | 0.010 |
Why?
|
Smoking | 1 | 2010 | 9053 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2013 | 15631 | 0.010 |
Why?
|
Heart Failure | 1 | 2014 | 11669 | 0.010 |
Why?
|